Merck (MRK) Cash from Operations (2009 - 2026)
Merck (MRK) reported Cash from Operations of 3918000000.0 for Q1 2026, up 56.72% year-over-year from 2500000000.0 in Q1 2025, and up 37.14% on a QoQ basis from 2857000000.0 in Q4 2025.
Merck (MRK) has 18 years of Cash from Operations data on file, last reported at 3918000000.0 in Q1 2026.
- Quarterly Cash from Operations rose 56.72% year-over-year to 3918000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 17890000000.0 (down 14.31% YoY) and the FY2025 annual result came in at 16472000000.0, down 23.27% from the prior year.
- Cash from Operations rose to 3918000000.0 in Q1 2026 per MRK's latest filing, from 2857000000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 9291000000.0 in Q3 2024 and bottomed at 246000000.0 in Q4 2023.
- The 5-year median for Cash from Operations is 3918000000.0 (2026), against an average of 4350529411.76.
- The widest annual swing landed in 2023, when Cash from Operations plunged 94.45%; it then soared 1302.44% in 2024.
- Tracing MRK's Cash from Operations over 5 years: stood at 4430000000.0 in 2022, then sank by 94.45% to 246000000.0 in 2023, then soared by 1302.44% to 3450000000.0 in 2024, then declined by 17.19% to 2857000000.0 in 2025, then jumped by 37.14% to 3918000000.0 in 2026.
- Per Business Quant, the three latest MRK Cash from Operations figures stand at 3918000000.0 (Q1 2026), 2857000000.0 (Q4 2025), and 7822000000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 5.33 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 2.51 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 3.83 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 3.92 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 2.19 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.54 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 2.62 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 1.10 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.92 Bn |
| Mar 31, 2026 | 3.92 Bn |
| Dec 31, 2025 | 2.86 Bn |
| Dec 31, 2025 | 2.86 Bn |
| Sep 30, 2025 | 7.82 Bn |
| Sep 30, 2025 | 7.82 Bn |
| Jun 30, 2025 | 3.29 Bn |
| Jun 30, 2025 | 3.29 Bn |
| Mar 31, 2025 | 2.50 Bn |
| Mar 31, 2025 | 2.50 Bn |
| Dec 31, 2024 | 3.45 Bn |
| Dec 31, 2024 | 3.45 Bn |
| Sep 30, 2024 | 9.29 Bn |
| Sep 30, 2024 | 9.29 Bn |
| Jun 30, 2024 | 5.64 Bn |
| Jun 30, 2024 | 5.64 Bn |
| Mar 31, 2024 | 3.09 Bn |
| Mar 31, 2024 | 3.09 Bn |
| Dec 31, 2023 | 246.00 Mn |
| Dec 31, 2023 | 246.00 Mn |
| Sep 30, 2023 | 7.72 Bn |
| Sep 30, 2023 | 7.72 Bn |
| Jun 30, 2023 | 3.70 Bn |
| Jun 30, 2023 | 3.70 Bn |
| Mar 31, 2023 | 1.34 Bn |
| Mar 31, 2023 | 1.34 Bn |
| Dec 31, 2022 | 4.43 Bn |
| Dec 31, 2022 | 4.43 Bn |
| Sep 30, 2022 | 5.60 Bn |
| Sep 30, 2022 | 5.60 Bn |
| Jun 30, 2022 | 4.30 Bn |
| Jun 30, 2022 | 4.30 Bn |
| Mar 31, 2022 | 4.76 Bn |
| Mar 31, 2022 | 4.76 Bn |
| Dec 31, 2021 | 5.10 Bn |
| Dec 31, 2021 | 5.10 Bn |
| Sep 30, 2021 | 4.80 Bn |
| Sep 30, 2021 | 4.80 Bn |
| Jun 30, 2021 | 1.99 Bn |
| Jun 30, 2021 | 1.99 Bn |
| Mar 31, 2021 | 1.24 Bn |
| Mar 31, 2021 | 1.24 Bn |
| Dec 31, 2020 | 3.41 Bn |
| Dec 31, 2020 | 3.41 Bn |
| Sep 30, 2020 | 1.58 Bn |
| Sep 30, 2020 | 1.58 Bn |
| Jun 30, 2020 | 1.92 Bn |
| Jun 30, 2020 | 1.92 Bn |
| Mar 31, 2020 | 707.00 Mn |
| Mar 31, 2020 | 707.00 Mn |
| Dec 31, 2019 | 238.00 Mn |
| Dec 31, 2019 | 238.00 Mn |
| Sep 30, 2019 | 4.23 Bn |
| Sep 30, 2019 | 4.23 Bn |
| Jun 30, 2019 | 3.08 Bn |
| Jun 30, 2019 | 3.08 Bn |
| Mar 31, 2019 | 1.34 Bn |
| Mar 31, 2019 | 1.34 Bn |
| Dec 31, 2018 | 3.59 Bn |
| Dec 31, 2018 | 3.59 Bn |
| Sep 30, 2018 | 2.79 Bn |
| Sep 30, 2018 | 2.79 Bn |
| Jun 30, 2018 | 3.38 Bn |
| Jun 30, 2018 | 3.38 Bn |
| Mar 31, 2018 | 1.16 Bn |
| Mar 31, 2018 | 1.16 Bn |
| Dec 31, 2017 | 4.02 Bn |
| Dec 31, 2017 | 4.02 Bn |
| Sep 30, 2017 | -1.17 Bn |
| Sep 30, 2017 | -1.17 Bn |
| Jun 30, 2017 | 3.32 Bn |
| Jun 30, 2017 | 3.32 Bn |
| Mar 31, 2017 | 286.00 Mn |
| Mar 31, 2017 | 286.00 Mn |
| Dec 31, 2016 | 3.63 Bn |
| Dec 31, 2016 | 3.63 Bn |
| Sep 30, 2016 | 2.97 Bn |
| Sep 30, 2016 | 2.97 Bn |
| Jun 30, 2016 | 1.60 Bn |
| Jun 30, 2016 | 1.60 Bn |
| Mar 31, 2016 | 2.17 Bn |
| Mar 31, 2016 | 2.17 Bn |
| Dec 31, 2015 | 4.25 Bn |
| Dec 31, 2015 | 4.25 Bn |
| Sep 30, 2015 | 3.31 Bn |
| Sep 30, 2015 | 3.31 Bn |
| Jun 30, 2015 | 2.70 Bn |
| Jun 30, 2015 | 2.70 Bn |
| Mar 31, 2015 | 2.28 Bn |
| Mar 31, 2015 | 2.28 Bn |
| Dec 31, 2014 | -1.04 Bn |
| Dec 31, 2014 | -1.04 Bn |
| Sep 30, 2014 | 4.35 Bn |
| Sep 30, 2014 | 4.35 Bn |
| Jun 30, 2014 | 2.32 Bn |
| Jun 30, 2014 | 2.32 Bn |
| Mar 31, 2014 | 2.36 Bn |
| Mar 31, 2014 | 2.36 Bn |
| Dec 31, 2013 | 3.03 Bn |
| Dec 31, 2013 | 3.03 Bn |
| Sep 30, 2013 | 3.95 Bn |
| Sep 30, 2013 | 3.95 Bn |
| Jun 30, 2013 | 2.34 Bn |
| Jun 30, 2013 | 2.34 Bn |
| Mar 31, 2013 | 2.34 Bn |
| Mar 31, 2013 | 2.34 Bn |
| Dec 31, 2012 | 1.81 Bn |
| Dec 31, 2012 | 1.81 Bn |
| Sep 30, 2012 | 3.14 Bn |
| Sep 30, 2012 | 3.14 Bn |
| Jun 30, 2012 | 2.92 Bn |
| Jun 30, 2012 | 2.92 Bn |
| Mar 31, 2012 | 2.15 Bn |
| Mar 31, 2012 | 2.15 Bn |
| Dec 31, 2011 | 3.23 Bn |
| Dec 31, 2011 | 3.23 Bn |
| Sep 30, 2011 | 4.58 Bn |
| Sep 30, 2011 | 4.58 Bn |
| Jun 30, 2011 | 2.85 Bn |
| Jun 30, 2011 | 2.85 Bn |
| Mar 31, 2011 | 1.72 Bn |
| Mar 31, 2011 | 1.72 Bn |
| Dec 31, 2010 | 3.54 Bn |
| Dec 31, 2010 | 3.54 Bn |
| Sep 30, 2010 | 2.59 Bn |
| Sep 30, 2010 | 2.59 Bn |
| Jun 30, 2010 | 3.33 Bn |
| Jun 30, 2010 | 3.33 Bn |
| Mar 31, 2010 | 1.37 Bn |
| Mar 31, 2010 | 1.37 Bn |
| Dec 31, 2009 | 2.24 Bn |
| Dec 31, 2009 | 2.24 Bn |
| Sep 30, 2009 | -312.10 Mn |
| Sep 30, 2009 | -312.10 Mn |
| Jun 30, 2009 | 749.00 Mn |
| Jun 30, 2009 | 749.00 Mn |
| Mar 31, 2009 | 712.60 Mn |
| Mar 31, 2009 | 712.60 Mn |